ArticleJournal of medical biochemistry2025
Comparison of the effects of citicoline and vascular rehabilitation capsules on neurotrophic and inflammatory factors in patients with cerebral infarction.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Butylphthalide (BP) is commonly used to treat vascular dementia (VD) following cerebral infarction (CI), but BP alone has limited efficacy. BP in combination with citicoline (COPC) or vascular rehabilitation capsules (VRC) is common in clinical practice, but few studies have compared the differences between these two treatment options. Methods: Ninety-eight patients with VD after CI who were seen in our hospital from April 2020 to June 2022 were selected as the study population. Among them, 52 patients received BP combined with COPC (BP+COPC group), while the rest 46 received BP combined with VRC (BP+VRC group). Fasting venous blood was drawn from the patients before and after treatment. The levels of neurotrophic factor [nerve growth factor (NGF), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF)], oxidative stress [superoxide dismutase (SOD), malondialdehyde (MDA)], and inflammatory factors [Tumor necrosis factor-a (TNF-a), Interleukin-1 (IL-1b), C-reactive protein (CRP)] were measured. Cognitive and neurological improvements were assessed using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) and the National Institute of Health Stroke Scale (NIHSS). In addition, the patient's cerebral hemodynamics were examined by CT. Results: After treatment, LOTCA increased in both groups and was higher in the BP+COPC group than in the BP+VRC group (P<0.05), while NIHSS decreased in the BP+COPC group than in the BP+VRC group (P<0.05). NSE, MDA, IL-1 , CRP, and TNF-a decreased in both groups after treatment, while NGF, BDNF, and SOD increased, again with more significant changes in the BP+COPC group (P<0.05). In addition, cerebral hemodynamics was more favourable in the BP+COPC group than in the BP+VRC group (P<0.05). Conclusions: BP combined with COPC has superior improvement in neurologic function in patients with VD after CI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.